Research programme: infectious disease vaccines - Nykode Therapeutics
Latest Information Update: 28 May 2024
At a glance
- Originator Vaccibody
- Developer Nykode Therapeutics
- Class DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Infections in Norway (Parenteral)
- 28 May 2024 No recent reports of development identified for preclinical development in Infections(Prevention) in Norway (Parenteral)
- 23 Nov 2021 Vaccibody is now called Nykode Therapeutics